source
- Gilead agrees to pay $1.28 billion upfront to China's PepStar for oral IL-23 inflammation drug candidateGilead Sciences announced a deal with Chinese biotech PepStar Therapeutics to acquire an early-stage oral IL-23 inhibitor. The agreement includes an upfront payment of roughly $1.28 billion for Pe…
- Few European-approved cancer drugs deliver high clinical benefit, analysis showsA new analysis of European regulator approvals between Jan 2022 and July 2026 finds that most newly approved cancer medicines provide limited clinical benefit. Out of 97 approved indications acros…